Colby Pharmaceutical Company (Colby), a privately held San Jose, CA based biopharmaceutical company, announced that it has acquired Othera Pharmaceuticals Inc. (Othera) of Conshohocken, PA.
OneMedPlace will be covering the European Tech Tour Association’s 3rd Annual Medtech Summit, taking place October 16-17 in Lausanne, Switzerland. Stay tuned for on-site coverage of programming and showcased companies, as well as a wrap-up of the event!
San Diego-based Freedom Meditech, Inc., a privately-held medical device company focused on commercialization of ophthalmic technologies for the detection of disease and management of patient health, last week announced it had secured a $2MM line of credit from Silicon Valley Bank.
The threat of infection in hospital and other treatment facilities have dramatically increased over the last few years. Antibiotics and other therapies have become impotent against certain pathogens and infections, increasing the need for research funding for creating new antibiotics. These three companies have the potential to solve a significant unmet medical need.
Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a clinical-stage biopharmaceutical company developing drugs for sexual dysfunction, inflammatory diseases and ophthalmological conditions has announced a manufacturing agreement with drug delivery maker Enthypharm Ltd for Zertane, Ampio’s drug for the treatment of premature ejaculation (PE).
OneMedRadio spoke with Ray Briscuso, Managing Partner and Producer of AdvaMed 2012, to learn about the can’t miss highlights in conference programming. Briscuso also discussed the history of the conference — how a gathering once geared toward trade association types has grown into one of the most important events in facilitating growth company finance in the sector.
The 6th Annual AdvaMed 2012 MedTech Conference kicks off October 1st for a 3-day event covering the hottest issues in the sector. This year, AdvaMed expects more than 2,100 attendees, 800 MedTech companies from 24 countries, 36 states and DC.
The San Diego-based pharmaceutical company has five approved products internationally, covering erectile dysfunction (Vitaros), side effects of cancer therapy (Totect and Granisol), coronary artery disease (Nitromist) and dry mouth (Aquoral). After a series of successes in strategic partnerships, acquisitions, peer review and clinical data in Q3, the company is garnering some serious attention.
To the scientific community, the Ebola virus is one of the most noxious pathogens identified to date. To the general population, the virus is dreadful, made especially frightening in pop culture.
September is Sickle Cell Awareness Month, a time when the medical community will gather with the patient population in the hopes of advancing research in this significant unmet medical need. One company, ADVENTRX Pharmaceuticals [NYSE: ANX], is attempting to engage the investor community and the sector’s most promising drug developers through the First Annual Sickle Cell Disease Therapeutics Conference, taking place September 19th, 2012 in New York City.
Copyright © 2024 | WordPress Theme by MH Themes